strated the most promising Minimum Inhibitory Concentration values comparing to others. The MIC values were ranged from 1.56 μg to 12.5 μg, especially compounds 5 c, 5 d, and 5 e displayed superior activity against tested strains compared to the standards. We also documented the results of anti-biofilm profiles for the compounds 5 c, 5 d, 5 e, 5 h, 5 m and 5 n. Based on the result, we noted that, the active derivatives 5 c, 5 d, and 5 e were strongly inhibited the biofilm of MSSA and MRSA biofilm growth with BFIC values ranging from 3.34 � 0.05 to 8.32 � 0.32 μg/mL. In accordance to the results of antibiofilm property, the compounds 5 c, 5 d and 5 e were further evaluated for bactericidal effect against selected Staphylococcus aureus mutant strains. In concern to the results, we confirmed that, the bactericidal effect was found significant with compound 5 d and followed by 5 c and 5 e. In silico docking simulation studies were performed to evaluate the molecular interactions of 5 c, 5 d, 5 e, 5 h, 5 m and 5 n compounds with the S.aureus (MRSA), Penicillin-binding protein (PDB ID: 1MWT, co-crystallised ligand inhibitor Pencillin G). Finally, the in silico pharmacokinetic profile was predicted for potent compounds using SWISS/ADME and pkCSM.